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Abstract
Background: Treatment non-adherence is a serious challenge to effective tuberculosis (TB) control in Tibet. In this
study we will pilot and evaluate the effectiveness of using new electronic monitors (e-monitors) and a smartphone
app to improve treatment adherence among new pulmonary TB patients in Tibet.
Methods: We will use a multicentre, parallel-group, individually randomised controlled, superiority trial with blinded
outcome evaluation and unblinded treatment. We will randomise new pulmonary TB outpatients (aged ≥ 15 years
old and free from communication impairment) from Shigatse, Tibet to either the intervention or control arm in a 1:
1 ratio at the time of their diagnosis. All patients will be treated according to the World Health Organisation
standard 6-month TB treatment regimen and the China National TB programme guidelines. Intervention arm
patients will be given their medication via e-monitors that have automatic voice reminders, and record medication
adherence data and share it with health staff via Cloud connection. Intervention patients will also be encouraged to
receive smartphone-based video-observed treatment if their adherence is problematic. Control arm patients will
receive their medication in e-monitors that will collect medication adherence history, but will have their reminder
function deactivated and are not linked to the app. The primary outcome is the rate of poor adherence, measured
monthly during treatment as a binary indicator where poor adherence means missing ≥ 20% of doses in a month.
We will conduct a qualitative process evaluation to explore operational questions regarding acceptability, cultural
appropriateness and burden of technology use, as well as a cost-effectiveness analysis and an analysis of the long-
term effects of the intervention on TB control.
Discussion: Our study is one of the first trials to evaluate the use of e-monitors and smartphone apps for customised
treatment support in low- and middle-income countries (LMICs). All intervention activities are designed to be
embedded into routine TB care with strong local ownership. Through the trial we intend to understand the feasibility
of our intervention, its effectiveness, its cost-effectiveness and its long-term impacts to inform future scale-up in remote
areas of China and other LMICs.
Trial registration: Current Controlled Trials, ID: ISRCTN52132803. Registered on 9 November 2018.
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Background
Treatment non-adherence is of paramount challenge in
tuberculosis (TB) control, and an important driver of the
emergence of TB drug resistance in Tibet, due to its
sparse population density, severe weather conditions,
long travel distances and shortage of human resources
to enable implementation of directly observed treatment
(DOT). Similar problems have been identified in other
parts of China [1]. Patients either self-administer their
treatment or receive inadequate supervision from a
health worker, normally the village physician [2, 3]. This
has resulted in poor treatment outcomes and high
default rates. Therefore, the Tibetan TB programme ur-
gently requires applicable and affordable alternatives to
improve treatment adherence.
Digital technology provides a promising tool to im-
prove treatment adherence. Existing literature suggests
that electronic reminders and medication packaging
interventions, such as Short Message Service (SMS)
reminders, electronic device reminders and pager re-
minders, markedly improve short-term adherence for
patients with chronic diseases [4, 5]. Typical characteris-
tics of these mhealth technologies include recording of
dosing events, storage of records, audiovisual reminders,
digital displays, real-time monitoring and performance
feedback. A trial in Ghana demonstrated that web-based
SMS reminders substantially improved patient adher-
ence to diabetic care and their clinical outcomes [6].
Recent studies have included electronic monitors
(e-monitors) as they deliver detailed, precise, and object-
ive data on daily adherence within a real-world setting
[7–10]. However, no studies have shown a long-term
effect for patients with chronic diseases [4, 5, 11, 12].
This research gap is particularly apparent for HIV pa-
tients undergoing chronic antiretroviral therapy [13, 14].
As such, the existing literature highlights the need to
tailor intervention delivery to meet versatile patient
demands. That is, the new technologies need to inter-
act beyond the patient interface to include multi-
media technologies, integrating models of patient care
delivery and connecting patients with healthcare pro-
fessionals [11, 13, 14].
In TB care, e-monitors and automated reminders have
emerged to improve the quality of care delivery with
accurate, real-time, detailed dosing information, and
dedicated communication channels between patients
and healthcare workers to discuss their concerns [15].
Real-time treatment adherence can support healthcare
workers to identify patients who need help and focussed
support, rather than having to spread their efforts
around all patients. In addition, new apps, such as
WeChat, can transmit texts, photos, audio and videos in
real-time, and have become popular among Tibetans.
This, therefore, provides the possibility of providing
video-observed treatment (VOT), an alternative to direct
observation using real-time or recorded videos for pa-
tients, based on patient treatment histories. Despite the
great potential, there is limited evidence supporting the
use of such new technologies to support TB manage-
ment. To our knowledge, worldwide there has only been
one randomised controlled trial (RCT) that assessed
using e-reminders to improve TB adherence, but this
study (based in the Chinese provinces of Heilongjiang,
Jiangsu, Hunan, and Chongqing) used an older
e-monitor that could not connect with smartphone apps
enabling VOT [16].
After piloting our intervention and study processes for
feasibility we will evaluate, via a RCT in two districts of
Shigatse in Tibet, whether using medication e-monitors
with Cloud connections improves the adherence of new
pulmonary TB patients to their medication, compared to
using inactivated e-monitors. The activated e-monitors
will provide patients with automated voice reminders to
take their medication, and by linking to a smartphone
app will enable patients to receive treatment education,
and will enable clinicians to access real-time patient
medication adherence data, and will enable real-time
patient-clinician communication, including VOT if
necessary. Monitors in the control arm will not be acti-
vated for voice reminders and not connected to smart-
phone apps. We will also explore implementation
questions regarding acceptability, cost-effectiveness and
long-term effects to inform future scale-up in remote
areas of China and other low- and middle-income coun-
tries (LMICs).
Methods
This protocol is reported according to the Standard
Protocol Items: Recommendations for Interventional
Trials (SPIRIT) guidelines (see Additional file 1 for de-
tails) [17].
Study design
We will use a multicentre, parallel-group, individually
randomised controlled trial with one intervention and
one control arm, using a 1:1 allocation ratio, to evaluate
whether the intervention is superior to the control
treatment. The study design is informed by the Medical
Research Council framework [18] on complex interven-
tions and implementation science principles [19] with an
embedded theory-based process evaluation [20] to
examine operational questions regarding acceptability,
cultural appropriateness, and burden of technology use.
In addition, we will conduct an incremental cost-effect-
iveness analysis to inform future scale-up. We also plan
to do a follow-up study to compare the intervention’s
impact on TB relapse rates after patients finish their
treatment.
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Setting
We will implement the study in two districts of Shigatse
Prefecture in China’s Tibetan Autonomous Region: one
urban area called Samzhubze, and one rural area called
Sa’gya. Shigatse Prefecture is located west of Lhasa with
an average altitude of 4000 m above sea level. Population
density in Shigatse is very low (4/km2). The prefecture
covers an area of 182,000 km2 of harsh and rugged ter-
rain with paved roads connecting county centres. Over
90% of its 800,000 residents are ethnic Tibetans. The
2014 TB survey revealed that the prevalence rate of pul-
monary TB was 758/100,000 (0.76%), almost twice
China’s national average [21, 22].
The two project sites currently face challenges to pro-
vide standard DOT to ensure TB treatment adherence.
TB care is only available from public health providers in-
cluding: (1) TB dispensaries located in Centre for Dis-
ease Control (CDC) facilities for clinical care and
general coordination, (2) township hospital (primary care
facilities) physicians for home visits and supervision of
village physicians, and (3) village physicians, often as
treatment supervisors. According to China’s National
Tuberculosis Programme (NTP) guidelines, new pul-
monary TB patients should be treated in the community
and should visit the district TB dispensary every month
to refill their medicines. However, the serious shortage
of health staff, plus the long travel distances and severe
weather conditions make regular home visits often
impossible. In practice, patients typically receive
self-administered therapy (SAT) with limited calls/visits
from health staff, and loss to follow-up rates have been
very high. Most patients visit the TB dispensary once
every 2 months, if not longer. Across Shigatse in 2016,
only 72% (769/1073) of new pulmonary TB cases com-
pleted treatment. Among patients who did not complete
treatment 83% (252/304) were lost to follow-up. Treat-
ment completion rates vary greatly by district. In our
two study districts a total of 269 patients were registered
in 2016, but only 38% (102) completed treatment, while
60% (162) were lost to follow-up and 1% (3) died. Many
patients, mostly poor farmers, were lost to follow-up
during the intensive phase as they received little educa-
tion and support from health workers due to a lack of
communication.
Eligibility and recruitment
In each district, patients with presumed TB and newly
confirmed pulmonary TB will be referred to the TB dis-
pensaries by health workers from other public and pri-
vate health facilities. Individuals can also present
themselves if suspecting having TB. All patients will be
diagnosed in the TB dispensary according to national
and international guidelines of TB care [23]. Eligible TB
patients are those: (1) aged ≥ 15 years, (2) who are
starting on standard 6-month short-course chemother-
apy on an outpatient basis, (3) are free from any com-
munication impairment (mental, visual, auditory or
speech), and (4) do not have any family members within
the same household who have already been enrolled into
the trial. We will recruit patients into the study via TB
physicians in the TB dispensaries who will screen pa-
tients for eligibility, and explain the study purpose and
obtain informed consent. The TB physicians also act as
TB coordinators responsible for reporting data to the
NTP. Based on existing routine TB data across the two
districts we expect to recruit 300 new pulmonary TB
patients in 15months. We will maximise patient enrol-
ment through fully informed consultations provided by
TB physicians.
Randomisation and blinding
Following recruitment, patients will be randomised to ei-
ther the intervention or the control arm in a near 1:1 ra-
tio, using a computer-generated randomised permuted
block design. The design will use random block lengths
of 2, 4 or 6, and include an initial unbalanced block,
with a maximum of one additional patient in either arm,
to further hide allocation sequences, which means that
the ultimate sample size and allocation ratio will vary
very slightly from what is planned dependent on the un-
balanced block. The allocation will be stratified by dis-
trict, with one district having approximately 160 patients
and another having approximately 140 patients, with a
near equal allocation ratio in each. JPH will generate the
allocation sequence, and will have no further role in the
randomisation or allocation process. The allocation
sequence will be used by the study team to print indi-
vidually numbered allocation cards, which will be placed
in sequentially numbered, sealed, opaque envelopes
before being delivered to study sites. The TB physicians
will allocate each recruited patient after their enrolment
by opening the correct envelope in the sequence, and
will provide the e-monitor setup according to the pa-
tient’s allocation. Research team members will educate
the TB physicians on the importance of following the
correct sequence, and local CDC staff will make monthly
visits to the TB dispensaries to carry out spot checks
and ensure the randomisation procedures are being cor-
rectly followed. It will not be possible to blind providers
or patients due to the nature of the intervention. How-
ever, we will take measures to ensure a blinded outcome
evaluation using: (1) the ‘PROBE’ design of blinded out-
come evaluation [24], and (2) blinding those analysing
the data to treatment status.
Treatment processes: all arms
All patients will be treated according to the standard
WHO DOTS programme and the China NTP guidelines
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using isoniazid, rifampin, ethambutol and pyrazinamide
for 2 months (3 months for sputum-smear-positive pa-
tients whose sputum smears have not converted to nega-
tive at the end of 2 months), followed by isoniazid and
rifampin for 4 months, under daily fix-dose combination
(FDC) for the entire treatment course [23]. According to
the NTP guidelines, patients will be given the choice of
SAT, or treatment with a supervisor, mostly village phy-
sicians but sometime a township hospital health worker.
The health workers who act as treatment supervisors
will receive RMB 60 (US$10) from the government when
completing 6-month support to a TB patient. The town-
ship hospital health workers also have the role of visiting
patients’ homes, and supervising village physicians. In
the two districts patients should visit the TB dispensary
at least every 2 months to meet with their TB physician
and refill their FDC medications using the e-monitor
box, which will collect data on the number of medica-
tions unused and refilled each time they are opened.
When patients meet with the TB physician they will also
count any leftover medicines. E-monitors will be
returned to district TB dispensaries at the end of treat-
ment and reused when possible.
Intervention arm
Figure 1 shows the framework of intervention strategies.
The e-monitors in the intervention arm have two main
functions beyond storing the TB medication. First, they
will remind patients to take their medicine on time using
human voice recordings. Second, they will transmit pa-
tients’ adherence history to a Cloud-based server, linking
with computers and a smartphone app. At recruitment
the TB physician will demonstrate how to use the
e-monitor box and WeChat app. The treatment super-
visor will visit the patient’s home within the first week of
treatment, and solve any remaining problems. During re-
cruitment or at the first home visit by the treatment
supervisor, a family member will be chosen to act as a
treatment supporter. The family member must live in
the same house as the patient, care about the patient,
and be literate in using the WeChat app. Then, patients
or their family members (if the patients are not able to
use a smartphone or WeChat) will be invited to setup
the WeChat app on their smartphones, and connect
with their TB physician and treatment supervisor. When
appointed, the family member will be trained by the TB
physician and the treatment supervisor about their re-
sponsibilities for providing psychological support to pa-
tients and facilitating patients use of the e-monitor and
the WeChat app. TB physicians and treatment supervi-
sors will add the patient or the family member into their
WeChat. Patients, treatment supporters, supervisors and
physicians will be able to have direct but distinct com-
munications. In addition, patients will receive audio/
video-based health education messages through WeChat
sent by the treatment supervisor and TB physician.
Using the WeChat app and also their computers con-
nected with e-monitors through the Cloud, health
workers will be able to monitor patient adherence his-
tory and outpatient visits. Patients who report consist-
ently taking their medications will continue SAT. TB
treatment supervisors or TB physicians will identify pa-
tients at high risk of being lost to follow-up based on
whether the patient: (1) expresses serious concerns
about maintaining their adherence, (2) skips three con-
secutive doses or (3) refuses to start or continue treat-
ment. Treatment supervisors will be trained that if their
patient is considered a high risk of becoming lost to
follow-up they should explore with the patient their rea-
sons for non-compliance and what help may be needed.
The treatment supervisor or TB physician will then try
to initiate VOT while providing any help needed. The
treatment supervisor will document the start and end
time of VOT. Patients who accept the invitation to begin
Fig. 1 Data flow between patients, health providers, and the server using electronic monitors and the WeChat app
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VOT will be given instructions either in the TB dispens-
ary or at home during the visit of their treatment super-
visor. Using the WeChat app VOT can be done with the
TB supervisor via a live video conversation or via re-
corded video/pictures showing them taking their medi-
cines. VOT will be provided until three consecutive
doses are completed on time, then the patient will
switch back to SAT using their e-monitors. Patients who
do not agree to VOT will be called daily by treatment
supervisors until three consecutive doses are completed.
We anticipate that less than 20% of TB patients will
need VOT, and mostly during the initial phase or at the
end of the treatment.
TB physicians, township public health staff and village
physicians will receive training on a revised operational
NTP guideline that incorporates using the e-monitor
box, WeChat, and VOT based on our previous experi-
ence [3], as well as how to communicate using the tools.
Control arm
The control arm will practice usual care except that pa-
tients will use deactivated e-monitors without automated
voice reminders to only collect treatment adherence
data. The data will be encrypted on the Cloud and will
thereby not be available to health workers during the
study. At each visit to the TB dispensary, patients will
refill their medications in their e-monitor boxes every 2
months. Treatment supervisors are advised to visit pa-
tients at least once a week according to the NTP guide-
line, but this will be at their own discretion. We will not
invite patients to connect with their TB physician or
treatment supervisors through the WeChat app. Treat-
ment supervisors will contact patients through trad-
itional means, such as physical visits or phone calls. We
will not select family treatment supporters.
Outcomes
The primary outcome will be the rate of poor adherence
measured per month across the 6/7 months of the stand-
ard WHO DOTS programme for new pulmonary TB pa-
tients. We will calculate the outcome from monthly level
data for each patient indicating the number of doses
missed per month, with poor adherence in a given
month defined as the patient having missed ≥ 20% of
doses in that month (equivalent to missing ≥ 6 out of 30
doses in a given month). This threshold has been com-
monly used in other disease areas [25] and in a similar
trial as a relevant indicator of treatment adherence [16].
Our secondary outcomes are: (1) the patient-level per-
centage of total doses missed over the 6/7 months of
treatment (calculated for each patient based on the total
number of doses missed out of the total possible number
of doses), and (2) a patient-level binary indicator of over-
all poor adherence (defined as ≥10% of total doses
missed, which is the NTP definition of non-adherence).
Our remaining secondary outcomes will be based on
World Health Organisation (WHO) standard definitions
of TB treatment outcomes [26]: (3) treatment comple-
tion rate (‘a TB patient who completed treatment with-
out evidence of failure but with no record to show that
sputum smear or culture results in the last month of
treatment and on at least one previous occasion were
negative, either because tests were not done or because
results are unavailable’), (4) loss to follow-up rate (‘a TB
patient who did not start treatment or whose treatment
was interrupted for two consecutive months or more’),
(5) poor treatment outcome rate (defined as death, treat-
ment failure (‘a TB patient whose sputum smear or
culture is positive at month 5 or later during treatment’)
or patient loss to follow-up), and (6) sputum conversion
rate at the end of the second month [27].
Sample size
As there are limited analytical sample size approaches
available for longitudinal outcomes we used a simulation
approach. We based our subsequent power calculation
on our primary outcome of monthly poor adherence,
and assumed a 40% monthly poor-adherence rate for the
control arm [16]. For our simulations we created six bin-
ary poor-adherence outcomes (i.e. one per treatment
month) for patients, varying the total number of patients
between simulations to explore power, but always
assuming a 1:1 treatment arm allocation ratio. The out-
comes were randomly generated from a Bernoulli distri-
bution with a fixed probability of success (i.e. probability
of monthly poor adherence), which was always set to 0.4
for the control arm, but was varied between simulations
for the intervention arm. In addition, in each simulation
all patients’ outcomes were generated with a fixed level
of correlation between their monthly outcomes, based
on an exchangeable correlation structure. These out-
come data were generated using the R package simstudy
[28], based on the Emrich and Piedmonte algorithm
[29]. We explored the effect on power of assuming an
AR1 correlation structure instead, but as our simulations
showed that this resulted in less conservative estimates
of power, and because we had no similar data to explore
the robustness of this assumption and no strong reason
to assume an AR1 structure, we assumed an exchange-
able structure instead. After generating the simulated
data we then used the R package geepack [30] to fit a
generalised estimating equation (GEE) to the data with
binomial errors and an identity link, which allowed esti-
mation of the absolute difference in treatment arm out-
come proportions (see the ‘Statistical analysis’ section for
more details) [31]. The GEE included a covariate for
treatment arm and a categorical variable for month. We
then extracted the Wald-based two-sided p value
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associated with the coefficient for the treatment effect
estimate. Finally, for each set of parameter assumptions we
repeated this process 1000 times and calculated the result-
ing power based on the proportion of p values ≤ 0.05. We
assumed no missing data due to patients who become lost
to follow-up still being able to contribute 100% of their
outcomes in the study. Assuming an expected monthly
poor-adherence rate of 40% in the control arm and a mod-
erate within-patient correlation between monthly poor-ad-
herence outcomes of 0.5, we require 300 patients to detect
an absolute reduction of 12 percentage points in the inter-
vention arm outcome (i.e. an intervention-arm monthly
poor-adherence rate of 28%) with 81.5% power.
Pilot stage
We will assess the feasibility of implementing the inter-
vention and running our trial processes through a pilot
study that will precede the main trial. Specifically, during
the preparation period we will invite four new pulmon-
ary TB patients (two in each district) to be randomised
into either the intervention or control arm as pilot cases,
allowing us to test the randomisation and recruitment
processes. We will then follow them up for 2 weeks to
assess the feasibility and acceptability of: (1) using the
e-monitor boxes for medication storage, (2) using the
Cloud-based server for monitoring adherence history,
and (3) using the WeChat app for patient-health worker
communication. We will also pilot test the feasibility of
using VOT in the two patients who are allocated to the
intervention. We will revise the implementation plan
based on our experiences from the pilot.
Process evaluation
Theoretical framework: we will employ an adapted ver-
sion of the Unified Theory of Acceptance and Use of
Technology (UTAUT) model [32, 33] to guide our
process evaluation to assess issues that influence
patients’ behaviour change in relation to both the tech-
nology used, such as acceptance, feasibility, appropriate-
ness, adaptability, as well as adherence behaviours
(Fig. 2). The UTAUT has been widely used to under-
stand information technology adoption in general. The
adapted UTAUT model has four constructs through
which to explore technology-oriented factors that shed
light on user experiences interacting with a given tech-
nology. These factors are: (1) performance expectancy,
(2) effort expectancy, (3) social influence, and (4) facili-
tating conditions. Performance expectancy includes the
perceived usefulness and personal outcome expectations
associated with technology use. Effort expectancy is the
perceived ease of use and complexity of the technology.
Social influence includes subjective norms and technol-
ogy use within a user’s social context. Facilitating condi-
tions include perceived behavioural control and wider
contextual circumstances that support the use of
technology. Together these factors provide a
Fig. 2 Theoretical framework to examine technology acceptance and use for adherence factors
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comprehensive understanding of the patient’s experi-
ence with the technology.
We also included adherence relevant aspects of the
WHO adherence framework into our theoretical frame-
work [34]. Condition-related factors are the illness-re-
lated demands faced by the patient which ultimately
impact the patients’ risk perception, treatment beliefs
and the priority that they place on adherence. While
therapy-related factors include side effects, treatment
duration, treatment failures and experience of side
effects [34]. These indicators may either motivate or dis-
suade patients from adhering to treatment plans.
Though our intervention may satisfy technology-oriented
needs of a patient, their treatment plan and their lived ex-
perience may pose unforeseen challenges to their behav-
ioural intention and change. All the above factors will be
considered with contextual and person-oriented factors
including gender, age, socioeconomic factors, experience
and voluntariness of technology use.
Our process evaluation is designed to explore factors
highlighted by the modified UTAUT model from the
perspective of patients, treatment supervisors, and physi-
cians. We will record the e-monitor’s defects, connectiv-
ity, and the operation within existing health and logistics
conditions through programme logbooks. We will also
record each supervision trip. We will report the propor-
tion of patients having a smartphone, able to enrol in,
and their technology use. We will measure the accuracy
of patient adherence history collected by e-monitors
against anti-TB drug refills/ counting in TB dispensaries
at each time of patient refills. District TB physicians will
record the persistence of using e-monitors over 6/7
months, the proportion of patients who need VOT, start
VOT, and the persistence of VOT (over 3 days until
satisfactory adherence).
We will conduct semi-structured in-depth interviews to
understand acceptability, cultural appropriateness, and
burden of technology use. We will recruit and interview 24
patients (18 from the intervention arm and 6 from the con-
trol arm), 12 family treatment supporters, at least 12 treat-
ment supervisors, six township treatment supervisors and
four TB physicians. Among patients in the intervention
arm, we aim to explore differences between patients who
demonstrate adherence and those who do not. We also
aim to explore differences in technology uptake, adoption
and sustained use between patients and identify whether
there are different stages of uptake and adoption. Ques-
tions will explore smartphone literacy, experience and
usability of the new technology, overall satisfaction, and
any concerns (e.g. understanding, learning experience, time
consumption, communication quality, confidentiality,
data-usage costs). Due to culture norms, we will pay
specific attention to women regarding confidentiality/priv-
acy issues in communications using WeChat and the VOT.
Economic study
We will conduct an incremental cost-effectiveness study
that will collect costs of the implementation package in-
cluding staff, equipment, and supplies – ‘incremental’ to
those required in usual (control arm) care. Overall incre-
mental cost-effectiveness ratios for the service interven-
tion and health outcomes, based on our primary and
secondary endpoint of treatment completion rate, will
be computed where possible. Simple unit costs of imple-
menting the intervention including cost per district and
per patient will be computed. The total per patient cost
will be calculated as the sum of three elements: (1) the
cost of clinic consultation estimated with physician’s
time input and unit salary; (2) the cost of patient
follow-up measured with frequency of home visit/using
WeChat, average time input for the two approaches and
their unit salaries, plus travel cost where applicable; and
(3) medication cost including inpatient and outpatient
health service charge, and indirect cost (travel, caregiver
cost, etc.) when a patient is hospitalised. The unit imple-
mentation cost will be calculated as the sum of: (1) cost
of staff time of both trainers and trainees; and (2) prep-
aration of intervention materials including e-monitors
and printings. Using published data, as available, we will
estimate the benefits to: human health including poten-
tially reduced multiple-drug resistance TB or TB death,
and productivity gains.
Follow-up study
We plan to follow up all patients using their national ID
numbers which will be recorded in the NTP reporting
system as a routine practice in Tibet. Follow-up will
start from when a participant completes their treatment
with any treatment outcomes including loss to
follow-up. We will track any relapse cases reported in
Tibet using the national TB reporting systems within 12
months of their treatment completion. Some patients
may travel to other provinces to work where national ID
number reporting is not mandatory for TB cases. To
mitigate this gap, we will conduct a short survey regard-
ing their TB status and the place of treatment (if any) by
the end of the follow-up study through their treatment
supervisors. We will also collect all mortalities using the
vital registration system in China where the national ID
has to be input. The primary endpoint of the follow-up
study is TB relapse and the secondary endpoint is mor-
tality. We will evaluate whether these outcomes differ
between the intervention and control arms using the
same methods of analysis as outlined below for the main
trial indicators. However, where patient follow-up data
cannot be collected we will conduct complete-case ana-
lyses by excluding those patients with missing data. This
study will be reported separately.
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Ethical approval
The trial protocol has obtained ethical approval from
the Office of Research Ethics at the University of To-
ronto (Ref: 36569) and the Ethics Review Committee
of the Tibet Centre for Disease Control and Preven-
tion (Ref: 006).
Data collection
In addition to the requirement by the China NTP, all
health staff in this study will have to sign an agreement
to keep all patient information confidential and only use
it for the purpose of TB care. All patient information
stored in the WeChat app at the provider’s end will be
deleted immediately once the patient has completed
treatment or been lost to follow-up. Patient information,
including name, age, sex, address, education, profession,
diagnosis, and treatment outcomes, will be routinely
collected by the NTP. We will also collect routinely re-
corded treatment outcomes data from the two districts,
including conversion at the second month, loss to
follow-up, death, and sputum smear results at the fifth
and sixth months. We will collect all these data during
monthly monitoring visits in the two districts. We will
use double entry and check a random subset of the data
to ensure data quality. We will use these data to calcu-
late our secondary indicators. The interventions are un-
likely to increase potential risks to patients. However,
any adverse events of the interventions will be reported
to the research coordinators in the Shigatse CDC by TB
physicians within 24 h and will be recorded in work logs.
For this study we will allocate a unique participant
number for each patient in our dataset to mask patient
identifiable information such as ID, names, and ad-
dresses. Research staff will only have access to the par-
ticipant number and non-identifying information such
as treatment outcomes. All the patients’ national ID
numbers will be recorded in the TB reporting system as
routinely required, which will be used to track any re-
lapse cases 12 months after the patient has completed
their treatment.
We will measure the adherence indicators based on
data collected by the e-monitor in both intervention and
control arms, which will be downloaded from the
Cloud-based database. To ensure that all missed doses
are accurately recorded we will cross-check the adher-
ence history recorded from e-monitors with pill counts
manually recorded at the end of each outpatient visit,
and we will record as the true value whichever is the
larger number of missed doses from the two data
sources. The TB physician will also conduct a short
questionnaire survey asking: (1) if patients have had
access to and/or used the WeChat and e-monitors, (2)
how much time patients have spent using the
e-monitors and WeChat, and (3) any medical costs. We
will also conduct a questionnaire for physicians and
treatment supervisors at the end of the trial period to
measure their time cost in supporting patient treatment.
We will collect implementation costs using researchers’
work logs, including the number of trainees, trainers’
labour and travel costs, and the cost of training materials
and the e-monitor boxes. We will also record and audio
tape the interviews with patients and health staff for the
process evaluation. Information from the interviews will
only be accessed by research staff, and anonymised
during analysis.
Statistical analysis
Our primary analysis population will be the ‘intention--
to-treat’ population, which will include all randomised
patients analysed according to their original treatment
allocation, irrespective of their subsequent adherence or
how they were actually treated. The Consolidated Stan-
dards of Reporting Trials (CONSORT) guidelines for
reporting parallel-group randomised trials recommend
presenting absolute measures of effect for binary out-
comes due to their increased relevance for practice and
policy, as well as relative measures of effect. Generalised
estimating equations (GEEs) have been shown to pro-
duce robust estimates of the absolute difference in treat-
ment effect for binary outcomes from multi-level trial
data [31]. Therefore, we will analyse our monthly binary
primary outcome of poor adherence using a GEE, with
binomial errors and an identity link, to estimate the ab-
solute difference in the proportion of poor adherence
across all treatment months between the intervention
and the control arms (intervention minus control). We
will assume an exchangeable correlation structure for
the repeated outcomes within individuals, and estimate
parameter standard errors as ‘Huber-White’ or ‘robust’
standard errors. In this analysis we will also adjust for ef-
fects (covariates) of month (as a categorical variable),
stratum, and a range of sociodemographic characteris-
tics: age (categorical: 15–49, 50 + years), sex, marriage
status (married, never married/not currently married),
and employment status (employed: farmer, employed:
other, unemployed/retired). We will base our principle
inference about the effectiveness of the intervention on
this main analysis. We will also repeat this analysis but
excluding all covariates other than month and stratum
as a sensitivity analysis to explore how robust the treat-
ment effect is when not adjusting for those potentially
imbalanced covariates. To explore how the treatment
effect differs between treatment months we will also re-
peat our main analysis but also include an interaction
between treatment group and month (as a categorical
variable) in the model, while also only including stratum
as an additional covariate because our parameter to sam-
ple size ratio will be constrained. Because the approach
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of using an identity link in a GEE with binomial errors is
not yet widely used, and to facilitate meta-analyses of
odds ratios (which are more commonly estimated) we
will also repeat the main analysis but using a GEE with
binomial errors and a logit link to estimate the odds ra-
tio for the odds of poor adherence in the intervention
arm compared to the control arm (based on taking the
exponential of the treatment effect coefficient). We do
not expect any missing data because we are only collect-
ing basic covariate data at baseline, and if patients are
lost to follow-up at any point then they will still contrib-
ute 100% of their primary outcome data because their
adherence status would be validly recorded as
non-adhering from the point at which they were lost to
follow-up. However, if their primary outcome data are
missing for an unexpected reason (e.g. loss of data) then
we will ensure that the ‘intention-to-treat’ analysis popu-
lation is maintained in all analyses by imputing the miss-
ing outcome data assuming the worst outcome of poor
adherence for those months where data are missing.
For our secondary outcome of the patient-level per-
centage of total doses missed over 6 months of treat-
ment, assuming the outcome is normally distributed we
will analyse it using a linear regression model including
the same covariates, other than month, as used in our
primary outcome main analysis. If the data are substan-
tially non-normally distributed we will apply a suitable
transformation to the data to achieve normality. If any
dose data are missing we will ensure that the ‘intention--
to-treat’ analysis population is maintained by imputing
the missing outcome data assuming the worst outcome,
i.e. that the dose(s) were missed. For all remaining
secondary outcomes, which are all binary, we will use a
‘logistic regression average-risk-difference’ analysis
approach to obtain absolute measures of treatment ef-
fect. In these analyses we will again adjust for the same
covariates, other than month, as used in the main pri-
mary outcome analysis. This approach has been shown
to provide robust estimates of absolute treatment effects
for RCTs with binary outcomes [35]. As with our pri-
mary outcome we will also conduct covariate-sensitivity
analyses for all secondary outcomes where we will repeat
the above analyses but without adjusting for any covari-
ates other than stratum. For our secondary outcome of
overall poor adherence if any dose data are missing we
will follow the same approach as for our analysis of the
patient-level percentage of total doses missed outcome.
All patients should be assigned a WHO standard TB
treatment outcomes. However, if any patients are miss-
ing these outcomes then we will assume the ‘worst’ out-
come (e.g. for the treatment completed outcome we
would assume they did not complete treatment).
Lastly, we will also conduct a small number of sub-
group analyses to explore whether treatment effects vary
between the subgroups. For our primary outcome we
will use the same main analysis approach planned above
(of using a binomial-identity GEE), but we will add an
interaction between treatment group and the relevant
subgroup identifier into the analysis to estimate the dif-
ference in treatment effect between the subgroups. We
will conduct subgroup analyses for our primary outcome
for the subgroups (1) sex, (2) age, and (3) travel time to
the relevant district TB dispensary, and we will compare
between men and women, less than the median age and
greater or equal than the median age, and less than the
median travel time and greater or equal than the median
travel time. We will also conduct subgroup analyses for
our secondary outcome of treatment completion for the
same range of subgroups. To do this we will use a logis-
tic regression model that includes covariates for treat-
ment, subgroup, the interaction between treatment and
subgroup, and the same range of covariates as noted in
our main analysis except month.
We will claim statistical significance at the 5% level,
and base our inferences on the two-sided p values
and associated 95% confidence intervals of the treat-
ment effect estimates. All outcomes will be analysed
at the end of the trial, and no interim analyses are
planned for this study.
Analysis of process evaluation
Both quantitative and qualitative data will be analysed.
Quantitative data will be summarised, described and
analysed using appropriate statistical methods, including
multiple linear regression for continuous outcomes and
multiple logistic regression for binary outcomes. Qualita-
tive data analysis will use a thematic approach to
discover emergent themes. Notes will be reviewed after
each interview to identify emergent topics and allow for
exploration in subsequent interviews. Data will be trans-
lated and transcribed, then analysed using NVivo 10.
Trial management
Prof Xiaolin Wei from the University of Toronto and
Dr. Jun Hu from Shigatse CDC will be the co-guarantors
of the trial who have full access to the trial dataset. An
external-member-led data management committee
(DMC) will be established to: (1) safeguard the safety
and privacy of patients involved, and to (2) ensure that
all data are collected according to agreed ethical guide-
lines, properly stored and only used for research pur-
poses. We will also form an external-member-led trial
steering committee (TSC), consisting of members from
China NTP, Tibetan TB programme, key members of
the trial team. Annual meetings will be held for both the
DMC and TSC. Important protocol modifications will
be discussed during the meetings.
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Discussion
Our study is one of the first trials to evaluate the use of
e-monitors linked to a smartphone app to customise pa-
tient support in LMICs and increase adherence to treat-
ment. The study fits well with the China NTP’s priority
to promote new technologies to improve TB care in
remote areas. Previous studies have revealed that only
new technologies that improved communications with
patients demonstrated benefits in improving disease
control outcomes in programmes [11, 12]. In our trial,
we will employ an e-monitor that has been piloted in
other geographically challenging areas of China (e.g.
Inner Mongolia and Xinjiang) and shown good usability.
Instead of launching a new app, we will link patients
with health worker through an existing app, WeChat,
which is widely used among Tibetans. Secondly, we will
actively involve patient family members who have good
literacy in using WeChat, and are willing to provide sup-
port to the patient physically and psychologically.
Thirdly, all intervention activities are designed to be em-
bedded into the routine practice of TB care with strong
local ownership. The project is co-led by Shigatse Centre
for Disease Control and University of Toronto, with a
trial unit established in Shigatse to coordinate trial activ-
ities. We will engage the TB programme at the national,
provincial, and frontline levels in developing guidelines
and training modules to ensure that the materials are
ready to be adapted to other remote areas through the
NTP. Fourthly, the trial is designed to fit into the
cutting-edge implementation science principles that in-
clude a theory-based process evaluation and economic
evaluation to inform scale-up in remote areas with simi-
lar challenges. Fifthly, we understand that adherence is a
two-way interactive process between the patient and
their physician(s). Our definition of the poor-adherence
rate reflects part of the adherence dynamics, such as
initiation, discontinuation, and implementation, that
change on a monthly basis [36]. This indicator, as used
in a previous similar trial, is more sensitive to measure
patient behaviour change compared with the overall
dose or adherence rate, and is more closely related to
the objective of DOTS in maintaining sustained adher-
ence throughout the 6/7 months of treatment [16].
There is a risk that patients may stop using e-monitors
during their treatment. We will train treatment supervi-
sors in both arms to check the status of e-monitors dur-
ing their visit to patients. Patients will be asked to take
their e-monitors to clinics for any medication refills.
When patients must travel for a long time during their
treatment, we will coordinate with TB physicians in their
influx areas to ensure that patients continue to use the
e-monitors.
Several other limitations and challenges need to be
noted. First, we cannot blind the health providers or
patients, which is very likely to introduce biases, particu-
larly performance bias (for both health worker and pa-
tients) and/or the Hawthorne effect. However, we will
minimise any risk of reporting bias by collecting patient
adherence history objectively and prospectively through
the e-monitors, which should prevent interference by
health providers or patients. We will also ensure that
health workers provide equal care to patients in both
arms during the training. Second, many TB patients in
Tibet are illiterate [22], but are able to use a smartphone
and WeChat because: (1) contacts in WeChat can be
recognised by icons, and (2) WeChat allows sending
audio and video recording by smartphones rather than
text alone. We will also employ a family member who
has good literacy in using WeChat to assist the patient.
Third, health providers, such as TB physicians and treat-
ment supervisors, are very likely to deal with patients
both from the intervention and control arms. To reduce
the contamination, we will ensure that correct proce-
dures are followed through our training and project
supervision visits. Fourth, molecular tests, such as cul-
ture and drug susceptibility tests, are not available in
Shigtase, while GeneXpert only has limited use because
of required equipment shortages. Thus, we are not able
to diagnose drug sensitive or resistance cases, although
this does reflect the reality of the context and mean the
trial is pragmatic in relation to diagnosis and case mix.
Fifth, we will provide patients in the control arm with a
deactivated e-monitor box which is different from rou-
tine practice. This may increase patients’ adherence to
medications in the control arm, which is most likely to
result in an estimate of the intervention’s effectiveness
that is lower than if we were comparing it to existing
practice without the use of e-monitor boxes. However,
we have made conservative estimates of the expected
rate of poor adherence and its difference between the
two arms. Having the deactivated e-monitor boxes in
the control arm also makes the trial less pragmatic.
Sixth, at this stage we envisage that patients with prob-
lems with their hearing, viewing, and speech will be hard
to be oriented using the new techniques in general, and
that they should receive special support and care to
complete the treatment regimens. We have, therefore,
excluded them from the trial, but this obviously limits
the generalisability of the results to those patients with-
out these issues.
Trial status and timelines
The trial was registered at Current Controlled Trials:
ISRCTN52132803 on 9 November 2018 (http://www.
isrctn.com/ISRCTN52132803). We started to recruit pa-
tients from 26 November 2018. At the original submis-
sion of the protocol, we have completed our pilot
studies and have recruited five patients.
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The study will be done over a 28-month period, with a
3-month preparation and pilot phase, a 15-month pa-
tient recruitment phase, with a 6/7-month treatment
phase for all patients, and a 3-month data analysis and
write-up stage. We will disseminate trial results through
research articles and policy briefs. We also plan to
follow-up all participants 12 months after they end treat-
ment using the TB reporting system to look at relapse
and mortality rates between the treatment arms. Results
of the follow-up study will be reported in a separate
paper from the trial results. See Fig. 3 for details of the
trial timeline.
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